Take Homes in SABCS: Metastatic Breast Cancer

Take Homes in SABCS: Metastatic Breast Cancer

Source: Healio Interview
Disclosures: Krop reports salary from AMAG Pharmaceuticals and Freeline Therapeutics; consulting fees from AstraZeneca, Bristol-Myers Squibb, Context Therapeutics, Daiichi Sankyo, Genentech/Roche, Ionis Pharmaceuticals/Novartis, Macrogenics, Merck, Seattle Genetics and Taiho Pharmaceutical; contracted research from Genentech and Pfizer; ownership interest in AMAG Pharmaceuticals, Freeline Therapeutics and Vertex; receiving honoraria from AstraZeneca, Celltrion and Genentech/Roche; and serving in leadership roles with AMAG Pharmaceuticals and Freeline Therapeutics.
December 26, 2021
1 min watch
Save

VIDEO: Positive trial results on selective estrogen receptor degrader 'exciting'

Source: Healio Interview
Disclosures: Krop reports salary from AMAG Pharmaceuticals and Freeline Therapeutics; consulting fees from AstraZeneca, Bristol-Myers Squibb, Context Therapeutics, Daiichi Sankyo, Genentech/Roche, Ionis Pharmaceuticals/Novartis, Macrogenics, Merck, Seattle Genetics and Taiho Pharmaceutical; contracted research from Genentech and Pfizer; ownership interest in AMAG Pharmaceuticals, Freeline Therapeutics and Vertex; receiving honoraria from AstraZeneca, Celltrion and Genentech/Roche; and serving in leadership roles with AMAG Pharmaceuticals and Freeline Therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, spoke with Healio about a recent study on elacestrant.

Results from the EMERALD trial — which assessed elacestrant (Menarini Group/Radius Health) in patients with ER-positive, HER2-negative advanced or metastatic breast cancer — were presented at this year’s San Antonio Breast Cancer Symposium.

Krop explained that the study showed superior efficacy with elacestrant, a selective estrogen receptor degrader (SERD), compared with standard-of-care endocrine therapy.

He said that “having this first randomized trial being a positive trial is exciting,” not just for elacestrant itself, “but the fact that there’s a number of other SERDs in development is good news for patients since we haven’t had a new endocrine therapy in 20-plus years.”

References:

Bardia A, et al. Abstract GS2-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.